| Literature DB >> 26435191 |
Yatao Yin1, Shuwei Qiu1, Ying Peng2.
Abstract
Gliomas are the most common and lethal type of primary malignant brain tumor. Due to the infiltrative nature and high resistance to standard first line treatment with combinations of radiation and chemotherapy, the prognosis of patient is very poor. Recently, accumulated evidence suggests that enhancer of zeste homolog 2 (EZH2) serves as an oncogene and is involved in multiple glioma cell processes, including cell cycle, invasion, glioma stem cell maintenance, drug and radiotherapy resistance and so on. In this review, we will focus on updating current knowledge of EZH2 in gliomas. Moreover, the regulation of EZH2 by microRNAs and long non-coding RNAs and the therapeutic strategies targeting EZH2 for gliomas will also be discussed.Entities:
Keywords: EZH2; Glioblastoma; Glioma stem cells; Long non-coding RNAs; MicroRNAs
Mesh:
Substances:
Year: 2015 PMID: 26435191 DOI: 10.1016/j.gene.2015.09.080
Source DB: PubMed Journal: Gene ISSN: 0378-1119 Impact factor: 3.688